APA (7th ed.) Citation

TE, P., JF, T., & AHR, V. (2025). ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy? Annals of surgical oncology, 32(6), 4225. https://doi.org/10.1245/s10434-024-16821-5

Chicago Style (17th ed.) Citation

TE, Pennington, Thompson JF, and Varey AHR. "ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?" Annals of Surgical Oncology 32, no. 6 (2025): 4225. https://doi.org/10.1245/s10434-024-16821-5.

MLA (9th ed.) Citation

TE, Pennington, et al. "ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?" Annals of Surgical Oncology, vol. 32, no. 6, 2025, p. 4225, https://doi.org/10.1245/s10434-024-16821-5.